赛诺菲持续加码数字化医疗 “极创联盟”收获首期硕果

2018-10-31 美通社 美通社

今天,全球领先的医药健康企业赛诺菲宣布,其在新兴市场设立的首个数字化创新平台“极创联盟”孕育的“极速项目”已取得首期成果。三家初创企业成功完成为期三个月的试点项目。未来五年,“极创联盟”计划追加6000万元人民币投资,用于开放创新及企业家精神培养,充分响应中国“互联网+医疗健康”举措。赛诺菲中国商务卓越部负责人 Pierre Faury 先生表示:“一直以来,赛诺菲都将数字化创

今天,全球领先的医药健康企业赛诺菲宣布,其在新兴市场设立的首个数字化创新平台“极创联盟”孕育的“极速项目”已取得首期成果。三家初创企业成功完成为期三个月的试点项目。未来五年,“极创联盟”计划追加6000万元人民币投资,用于开放创新及企业家精神培养,充分响应中国“互联网+医疗健康”举措。

赛诺菲中国商务卓越部负责人 Pierre Faury 先生表示:“一直以来,赛诺菲都将数字化创新作为公司战略的重要组成部分,‘极创联盟’的成立让我们能够与外部互联网生态系统更紧密地结合。此次与互联网初创企业的‘跨界’合作,是我们在商业模式上的又一次创新和突破,整合内外部的智慧,为广大医学专业人士和患者提供更高效的一体化解决方案。”

赛诺菲中国商务卓越部负责人Pierre Faury先生 
赛诺菲中国商务卓越部负责人Pierre Faury先生

作为“极创联盟”推出的首个项目,“极速项目”在今年4月底向初创企业发出首期“英雄帖”,发掘并培育有潜力的数字化医疗项目。

今天,全球领先的医药健康企业赛诺菲宣布,其在新兴市场设立的首个数字化创新平台“极创联盟”孕育的“极速项目”已取得首期成果。三家初创企业成功完成为期三个月的试点项目。

RIKAI Labs,Researchably 和博知科技三家初创企业携手赛诺菲,开展试点项目,开发有潜力的数字医疗项目,其中一家初创企业代表表示:“很高兴能够加入‘极速项目’并最终胜出,在过去数月的协力创新中,我们收获良多。赛诺菲在行业洞见、产品和疾病管理方面分享了丰富的经验,提供专业的指导,期待未来能与赛诺菲有更多深入的合作。”

赛诺菲中国“极创联盟”首期“极速项目”毕业典礼合影 
赛诺菲中国“极创联盟”首期“极速项目”毕业典礼合影

同时,赛诺菲宣布第二期“极速项目”已全面启动。未来,“极创联盟”还将在医生和患者管理、患者依从性提升、人工智能及数字化机器人助理、大数据等领域与初创企业开展广泛合作。 

关于赛诺菲

赛诺菲致力于帮助人们应对健康挑战。我们是一家全球生物制药公司,专注人类健康。我们用疫苗预防疾病,提供创新的治疗方案减轻病痛和困扰。我们助力罹患罕见病的极少数人,也支持长期受慢性病困扰的千万患者。

赛诺菲共有10万余名员工,遍及100多个国家,致力于将科学创新转化为医疗健康解决方案。

Sanofi, Empowering Life. 赛诺菲,让生命绽放。

关于赛诺菲中国

赛诺菲于1982年进入中国,总部位于上海,业务覆盖制药、人用疫苗和消费者保健。集团在北京、天津、沈阳、济南、杭州、南京、武汉、成都、广州、福州和乌鲁木齐共设有11个区域办公室,并在北京、杭州和深圳建有三家生产基地。赛诺菲在中国约有9,500名员工。

赛诺菲在上海设有中国研发中心和亚太研发总部,在成都设有全球研发运营中心。我们的研发专注于中国与亚太的高发疾病,如肝病、糖尿病、肿瘤和血管疾病。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1659820, encodeId=8c031659820fe, content=<a href='/topic/show?id=c74e5e667e5' target=_blank style='color:#2F92EE;'>#数字化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57667, encryptionId=c74e5e667e5, topicName=数字化医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12625051837, createdName=zhangbaojun, createdTime=Thu Sep 05 01:47:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363461, encodeId=5669136346112, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496644, encodeId=758d14966443f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351129, encodeId=216b3511293f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 01 06:49:04 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351024, encodeId=f1cf351024f0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Oct 31 09:02:18 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1659820, encodeId=8c031659820fe, content=<a href='/topic/show?id=c74e5e667e5' target=_blank style='color:#2F92EE;'>#数字化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57667, encryptionId=c74e5e667e5, topicName=数字化医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12625051837, createdName=zhangbaojun, createdTime=Thu Sep 05 01:47:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363461, encodeId=5669136346112, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496644, encodeId=758d14966443f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351129, encodeId=216b3511293f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 01 06:49:04 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351024, encodeId=f1cf351024f0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Oct 31 09:02:18 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1659820, encodeId=8c031659820fe, content=<a href='/topic/show?id=c74e5e667e5' target=_blank style='color:#2F92EE;'>#数字化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57667, encryptionId=c74e5e667e5, topicName=数字化医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12625051837, createdName=zhangbaojun, createdTime=Thu Sep 05 01:47:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363461, encodeId=5669136346112, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496644, encodeId=758d14966443f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351129, encodeId=216b3511293f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 01 06:49:04 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351024, encodeId=f1cf351024f0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Oct 31 09:02:18 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
    2018-11-01 zexyw04
  4. [GetPortalCommentsPageByObjectIdResponse(id=1659820, encodeId=8c031659820fe, content=<a href='/topic/show?id=c74e5e667e5' target=_blank style='color:#2F92EE;'>#数字化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57667, encryptionId=c74e5e667e5, topicName=数字化医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12625051837, createdName=zhangbaojun, createdTime=Thu Sep 05 01:47:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363461, encodeId=5669136346112, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496644, encodeId=758d14966443f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351129, encodeId=216b3511293f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 01 06:49:04 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351024, encodeId=f1cf351024f0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Oct 31 09:02:18 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
    2018-11-01 1dd8a7c5m95(暂无匿称)

    好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1659820, encodeId=8c031659820fe, content=<a href='/topic/show?id=c74e5e667e5' target=_blank style='color:#2F92EE;'>#数字化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57667, encryptionId=c74e5e667e5, topicName=数字化医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12625051837, createdName=zhangbaojun, createdTime=Thu Sep 05 01:47:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363461, encodeId=5669136346112, content=<a href='/topic/show?id=46135e6658f' target=_blank style='color:#2F92EE;'>#数字化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57665, encryptionId=46135e6658f, topicName=数字化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e05e201, createdName=appleandpeer, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496644, encodeId=758d14966443f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Thu Nov 01 23:47:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351129, encodeId=216b3511293f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Nov 01 06:49:04 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351024, encodeId=f1cf351024f0, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed Oct 31 09:02:18 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
    2018-10-31 kafei

    了解一下谢谢

    0

相关资讯

Sci Tran Med:不止会吐口水,神兽羊驼携“天生技能”助推抗体药物进入新时代

世界之大,无奇不有。在山的那边海的那边,总有许多奇特的动物,但恐怕没有一种会像羊驼一样在遥远的大洋彼岸拥有如此多的拥护者了,甚至还获得了“神兽”的封号。

全球疫苗四大巨头之一赛诺菲3.5亿欧元在加拿大建立新疫苗工厂

赛诺菲于4月12日宣布将斥资3.5亿欧元在加拿大多伦多建立新疫苗工厂,这是该公司有史以来在单一制造工厂中最大规模的一次投资,此举也更加凸显赛诺菲巴斯德疫苗业务对赛诺菲的重要性。

真实世界的数据支持赛诺菲的Toujeo用于I型糖尿病

赛诺菲公布了来自英国真实世界的研究数据,显示其长效基础胰岛素类似物Toujeo在治疗I型糖尿病患者中的功效。这些数据首次在芝加哥内分泌协会第100届年会暨博览会ENDO 2018上发布,表明该药物与患有该病症的患者的HbA1c的显着改善,具有统计学意义,平均差异从基线至六个月的-4.4毫摩尔/摩尔。该研究还显示,在Toujeo(Gla-300)开始治疗后报告糖尿病酮症酸中毒(DKA)或严重低血糖的

赛诺菲将Dupixent用于严重哮喘

美国监管机构已接受Sanofi / Regeneron的生物制剂Dupixent作为某些成人和青少年中度至重度哮喘的辅助治疗药物。Dupixent是一种人类单克隆抗体,专门用于抑制IL-4和IL-13的信号传导,IL-4和IL-13是导致中度至重度哮喘中II型炎症的两种关键信号蛋白。该药物已经在市场上用于治疗特应性皮炎。哮喘的提交资料包括III期LIBERTY ASTHMA VENTURE研究的数

2018赛诺菲希望义工日活动在全国13个城市再起航

上海2018年10月22日-- 今天,“赛诺菲希望义工日”在全国包括北京、上海、广州等13个城市再度起航!数百名赛诺菲义工以“绽放童颜,‘跳’战病痛”为主题,联合15家专业公益组织,深入当地社区、医院和康复机构,通过开展丰富有趣的义工活动,回应病童渴望快乐成长的心理需求,向正在经历病痛、期待痊愈的患儿们传递积极向上的“跳蛙精神”,增强他们战胜病痛的勇气和乐观生活的信心。 上海“倾听孩

赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘

赛诺菲和Regeneron制药公司近日宣布,FDA已经正式批准Dupixent(dupilumab)作为一种附加维持疗法,用于12岁及以上患有嗜酸性粒细胞表型或口服皮质类固醇依赖性的中重度哮喘患者。